Imatinib in Systemic Sclerosis

Status Completed

Clinical Trial Summary

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs and widespread vasculopathy. Patients with SSc are classified according to the extent of cutaneous sclerosis: patients with limited SSc have skin thickening of the face, neck, and distal extremities, while those with diffuse SSc have involvement of the trunk, abdomen, and proximal extremities as well. The disease course varies depending on the subtype of SSc. However, common features that result in significant morbidity and mortality, in addition to cutaneous fibrosis, include Raynaud's phenomenon and digital ulcerations, interstitial lung disease (ILD), and pulmonary arterial hypertension (PAH). Current therapeutic options for patients with SSc and these clinical manifestations have shown limited efficacy.

Imatinib antagonizes specific tyrosine kinases that mediate fibrotic pathways involved in the pathogenesis of SSc, including c-Abl, a downstream mediator of transforming growth factor (TGF)-beta, and platelet derived growth factor (PDGF) receptors. The efficacy of imatinib has also been reported in the treatment of patients with refractory idiopathic PAH through its effects on vascular remodeling. Based on the mechanism of action and preliminary patient data, we hypothesize that imatinib may be effective in the treatment of the fibrotic and vasculopathic features of patients with SSc. This is an open label pilot study to evaluate the safety and efficacy of imatinib in patients with progressive SSc refractory to other treatment(s). Validated measures of skin thickness and disease activity will be determined over 6-months of therapy and compared with baseline measures.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00506831
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	July 2007
Completion date	September 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03965780` - The SPIN - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED)	N/A
Terminated	`NCT02558543` - Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis	Phase 2
Withdrawn	`NCT01202045` - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients	N/A
Terminated	`NCT01445821` - Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial	Phase 3
Recruiting	`NCT05878717` - A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease	Phase 3
Recruiting	`NCT03559465` - Profibrosing Role of B Lymphocytes in Patients With Systemic Sclerosis.	N/A
Not yet recruiting	`NCT03610217` - Pragmatic Clinical Trials in Scleroderma	N/A
Completed	`NCT02655640` - The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis	N/A
Completed	`NCT05622578` - Phenotyping of Chronic Pain in Diffused Systemic Scleroderma	N/A
Recruiting	`NCT04804930` - Trichoscopy and Systemic Scleroderma
Completed	`NCT03675581` - A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)	Phase 1
Completed	`NCT03221257` - Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate	Phase 2
Recruiting	`NCT05559580` - A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms	Phase 2
Completed	`NCT00442611` - A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)	Phase 1/Phase 2
Completed	`NCT00001330` - Study of Silicone-Associated Connective Tissue Diseases	N/A
Completed	`NCT02597933` - A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis	Phase 3
Not yet recruiting	`NCT05821335` - Leap Motion Based Gamefication Exercises in the Individuals With Systemic Sclerosis	N/A
Completed	`NCT00333437` - Pulmonary Involvement in Scleroderma: A Clinical Study of the Safety and Efficacy of Mycophenolate Mofetil in Scleroderma Patients With Lung Involvement	N/A
Completed	`NCT00025818` - Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome	Phase 3
Not yet recruiting	`NCT05351060` - Novel Splinting Technique Using 3D Models	N/A